Cargando…

Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?

Background: Empiric antibiotic therapy for suspected vertebral osteomyelitis (VO) should be initiated immediately in severely ill patients, and might be necessary for culture-negative VO. The current study aimed to identify differences between community-acquired (CA) and healthcare-associated (HA) V...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Siegmund, Frömming, Astrid, Walter, Nike, Freigang, Viola, Neumann, Carsten, Loibl, Markus, Ehrenschwender, Martin, Alt, Volker, Rupp, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615006/
https://www.ncbi.nlm.nih.gov/pubmed/34827348
http://dx.doi.org/10.3390/antibiotics10111410
_version_ 1784603999944572928
author Lang, Siegmund
Frömming, Astrid
Walter, Nike
Freigang, Viola
Neumann, Carsten
Loibl, Markus
Ehrenschwender, Martin
Alt, Volker
Rupp, Markus
author_facet Lang, Siegmund
Frömming, Astrid
Walter, Nike
Freigang, Viola
Neumann, Carsten
Loibl, Markus
Ehrenschwender, Martin
Alt, Volker
Rupp, Markus
author_sort Lang, Siegmund
collection PubMed
description Background: Empiric antibiotic therapy for suspected vertebral osteomyelitis (VO) should be initiated immediately in severely ill patients, and might be necessary for culture-negative VO. The current study aimed to identify differences between community-acquired (CA) and healthcare-associated (HA) VO in terms of clinical presentation, causative pathogens, and antibiotic susceptibility. Methods: Cases of adult patients with VO treated at a German university orthopaedic trauma center between 2000 and 2020 were retrospectively reviewed. Patient history was used to distinguish between CA and HA VO. Susceptibility of antibiotic regimens was assessed based on antibiograms of the isolated pathogens. Results: A total of 155 patients (with a male to female ratio of 1.3; and a mean age of 66.1 ± 12.4 years) with VO were identified. In 74 (47.7%) patients, infections were deemed healthcare-associated. The most frequently identified pathogens were Staphylococcus aureus (HAVO: 51.2%; CAVO: 46.8%), and Coagulase-negative Staphylococci (CoNS, HAVO: 31.7%; CAVO: 21.3%). Antibiograms of 45 patients (HAVO: n = 22; CAVO: n = 23) were evaluated. Significantly more methicillin-resistant isolates, mainly CoNS, were found in the HAVO cohort (27.3%). The highest rate of resistance was found for cefazolin (HAVO: 45.5%; CAVO: 26.1%). Significantly higher rates of resistances were seen in the HAVO cohort for mono-therapies with meropenem (36.4%), piperacillin–tazobactam (31.8%), ceftriaxone (27.3%), and co-amoxiclav (31.8%). The broadest antimicrobial coverage was achieved with either a combination of piperacillin–tazobactam + vancomycin (CAVO: 100.0%; HAVO: 90.9%) or meropenem + vancomycin (CAVO: 100.0%; HAVO: 95.5%). Conclusion: Healthcare association is common in VO. The susceptibility pattern of underlying pathogens differs from CAVO. When choosing an empiric antibiotic, combination therapy must be considered.
format Online
Article
Text
id pubmed-8615006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86150062021-11-26 Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis? Lang, Siegmund Frömming, Astrid Walter, Nike Freigang, Viola Neumann, Carsten Loibl, Markus Ehrenschwender, Martin Alt, Volker Rupp, Markus Antibiotics (Basel) Article Background: Empiric antibiotic therapy for suspected vertebral osteomyelitis (VO) should be initiated immediately in severely ill patients, and might be necessary for culture-negative VO. The current study aimed to identify differences between community-acquired (CA) and healthcare-associated (HA) VO in terms of clinical presentation, causative pathogens, and antibiotic susceptibility. Methods: Cases of adult patients with VO treated at a German university orthopaedic trauma center between 2000 and 2020 were retrospectively reviewed. Patient history was used to distinguish between CA and HA VO. Susceptibility of antibiotic regimens was assessed based on antibiograms of the isolated pathogens. Results: A total of 155 patients (with a male to female ratio of 1.3; and a mean age of 66.1 ± 12.4 years) with VO were identified. In 74 (47.7%) patients, infections were deemed healthcare-associated. The most frequently identified pathogens were Staphylococcus aureus (HAVO: 51.2%; CAVO: 46.8%), and Coagulase-negative Staphylococci (CoNS, HAVO: 31.7%; CAVO: 21.3%). Antibiograms of 45 patients (HAVO: n = 22; CAVO: n = 23) were evaluated. Significantly more methicillin-resistant isolates, mainly CoNS, were found in the HAVO cohort (27.3%). The highest rate of resistance was found for cefazolin (HAVO: 45.5%; CAVO: 26.1%). Significantly higher rates of resistances were seen in the HAVO cohort for mono-therapies with meropenem (36.4%), piperacillin–tazobactam (31.8%), ceftriaxone (27.3%), and co-amoxiclav (31.8%). The broadest antimicrobial coverage was achieved with either a combination of piperacillin–tazobactam + vancomycin (CAVO: 100.0%; HAVO: 90.9%) or meropenem + vancomycin (CAVO: 100.0%; HAVO: 95.5%). Conclusion: Healthcare association is common in VO. The susceptibility pattern of underlying pathogens differs from CAVO. When choosing an empiric antibiotic, combination therapy must be considered. MDPI 2021-11-18 /pmc/articles/PMC8615006/ /pubmed/34827348 http://dx.doi.org/10.3390/antibiotics10111410 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lang, Siegmund
Frömming, Astrid
Walter, Nike
Freigang, Viola
Neumann, Carsten
Loibl, Markus
Ehrenschwender, Martin
Alt, Volker
Rupp, Markus
Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?
title Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?
title_full Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?
title_fullStr Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?
title_full_unstemmed Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?
title_short Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?
title_sort is there a difference in clinical features, microbiological epidemiology and effective empiric antimicrobial therapy comparing healthcare-associated and community-acquired vertebral osteomyelitis?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615006/
https://www.ncbi.nlm.nih.gov/pubmed/34827348
http://dx.doi.org/10.3390/antibiotics10111410
work_keys_str_mv AT langsiegmund isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT frommingastrid isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT walternike isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT freigangviola isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT neumanncarsten isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT loiblmarkus isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT ehrenschwendermartin isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT altvolker isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis
AT ruppmarkus isthereadifferenceinclinicalfeaturesmicrobiologicalepidemiologyandeffectiveempiricantimicrobialtherapycomparinghealthcareassociatedandcommunityacquiredvertebralosteomyelitis